Metformin and statins: a possible role in high-risk prostate cancer | Zendy

Giovanna Cadeddu | Zendy; A. Hervás | Zendy; M. Martín | Zendy; Lira Pelari-Mici | Zendy; Kathy Ytuza-Charahua de Kirsch | Zendy; Antonio Hernández-Corrales | Zendy; Carmen Vallejo-Ocaña | Zendy; Sara Sastre-Gallego | Zendy; Eliseo Carrasco-Esteban | Zendy; S. Sancho | Zendy; Fernando LópezCampos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metformin and statins: a possible role in high-risk prostate cancer

Author(s) -

Giovanna Cadeddu,

A. Hervás,

M. Martín,

Lira Pelari-Mici,

Kathy Ytuza-Charahua de Kirsch,

Antonio Hernández-Corrales,

Carmen Vallejo-Ocaña,

Sara Sastre-Gallego,

Eliseo Carrasco-Esteban,

S. Sancho,

Fernando LópezCampos

Publication year - 2020

Publication title -

reports of practical oncology and radiotherapy

Language(s) - English

Resource type - Journals

eISSN - 2083-4640

pISSN - 1507-1367

DOI - 10.1016/j.rpor.2019.12.027

Subject(s) - metformin , medicine , prostate cancer , oncology , androgen deprivation therapy , cancer , prostatectomy , urology , insulin

There is increasing evidence that statins and oral anti-diabetic drugs, such as metformin, can have a favorable role in advanced prostate cancer treatment.Metformin has been shown to inhibit proliferation of tumor cells in vitro and statins inhibit carcinogenesis by suppressing angiogenesis/invasion mechanisms. However, clinical evidence on the protective effect of these drugs is still weak.The purpose of this study is to analyze if these drugs have an impact on Biochemical-Failure-Free-Survival (BFFS) and on Distant-Failure-Free-Survival (DFFS) in localized high-risk prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research